PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Product Life Cycle Management Key to Sustaining Revenue Growth in European Gastroenterology Therapeutics Market - Frost & Sullivan finds that the European Gastroenterology Therapeutics Market was valued at $10.64 billion in 2006 and estimates this to reach $11.74 billion in 2013
Product Life Cycle Management Key to Sustaining Revenue Growth in European Gastroenterology Therapeutics Market

 

NewswireToday - /newswire/ - London, United Kingdom, 2007/11/26 - Frost & Sullivan finds that the European Gastroenterology Therapeutics Market was valued at $10.64 billion in 2006 and estimates this to reach $11.74 billion in 2013.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The European gastroenterology therapeutics market is in the maturity phase and is highly competitive. Brand recognition and product efficacy drive product acceptance in the market. Downward price pressures caused by cost control measures adopted by European governments and the extensive availability of generics are negatively affecting overall revenue growth. Efficient life cycle management and product innovation will be key to sustaining market expansion.

Frost & Sullivan (pharma.frost.com) finds that the European Gastroenterology Therapeutics Market was valued at $10.64 billion in 2006 and estimates this to reach $11.74 billion in 2013.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the investment analysis and growth opportunities in the European Gastroenterology Therapeutics Market, then send an email to Radhika Menon Theodore, Corporate Communications, at rmtheodore[.]frost.com, with your full name, company name, title, telephone number, fax number, and email address. Upon receipt of the above information, an overview will be sent to you by email.

"The gastroenterology therapeutics market in Europe is driven principally by the proton pump inhibitors (PPI) segment," notes Frost & Sullivan Research Analyst John Paul. "Poor lifestyles continue to promote the uptake of gastroenterology therapies, and PPI, with its superior efficacy, will help maintain revenue growth."

PPIs are replacing the less effective Histamine-2 receptor antagonists and antacids as the primary choice for treating gastroesophageal reflux and peptic ulcer diseases. The lack of innovative therapies in the pipeline implies the continued dominance of PPIs in the market.

Price control regulations implemented by European governments are severely affecting the revenues of market participants. Companies are being forced to reduce the price of their branded products to compete in the market, where generics are heavily recommended.

"The existing products in the market have little differentiation and do not cure the cause of the diseases," explains Paul. "Reference pricing policies implemented by governments are exerting downward pressures on the prices of branded PPIs because of the extensive availability of generic equivalents. Producing innovative products to treat the causes of the diseases is the only solution to prevent decreasing revenues."

The inflammatory bowel diseases market is a potential target for incumbent and prospective competitors. Patent protection and the expansion of the patient base through reformulation and approval of existing drugs for untargeted disease segments will be vital in the gastroesophageal reflux and peptic ulcer diseases markets. While anti-inflammatory agents and immunosuppressive agents provide relief for patients with inflammatory diseases, questionable side-effect profiles will stimulate the need for improved therapies.

European Gastroenterology Therapeutics Market is part of the Pharmaceutical & Biotechnology Growth Partnership Service Programme, which also includes research in the following markets: European bladder cancer therapeutics market, European prostrate cancer therapeutics market, European head and neck cancer therapeutics market and European testosterone replacement therapies market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

About Frost & Sullivan
Frost & Sullivan, the Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Product Life Cycle Management Key to Sustaining Revenue Growth in European Gastroenterology Therapeutics Market

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Radhika Menon Theodore 
rmtheodore[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)